Literature DB >> 12797445

Measles virus and dendritic cell functions: how specific response cohabits with immunosuppression.

C Servet-Delprat1, P O Vidalain, H Valentin, C Rabourdin-Combe.   

Abstract

Measles virus (MV) infection induces both an efficient MV-specific immune response and a transient but profound immunosuppression characterised by a panlymphopenia that occasionally results in opportunistic infections responsible for a high rate of mortality in children. On the basis of in vitro studies, the putative roles of dendritic cells (DCs) in MV infection are discussed. (1) DCs could participate in anti-MV innate immunity because MV turns on TNF-related apoptosis-inducing ligand (TRAIL)-mediated DC cytotoxicity. (2) Cross-priming by non-infected DCs might be the route of MV adaptive immune response. (3) After CD40-ligand activation in secondary lymphoid organs, MV-infected DCs could initiate the formation of Warthin-Finkeldey multinucleated giant cells, replicating MV and responsible for in vivo spreading of MV. (4) We review how integrated viral attack of the host immune system also targets DCs: Progress in understanding the immunobiology of MV-infected DCs that could account for MV-induced immunosuppression observed in vivo is presented and their potential role in lymphopenia is underlined. In conclusion, future research directions are proposed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797445     DOI: 10.1007/978-3-662-06508-2_5

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  20 in total

1.  Measles virus (MV) nucleoprotein binds to a novel cell surface receptor distinct from FcgammaRII via its C-terminal domain: role in MV-induced immunosuppression.

Authors:  David Laine; Marie-Claude Trescol-Biémont; Sonia Longhi; Geneviève Libeau; Julien C Marie; Pierre-Olivier Vidalain; Olga Azocar; Adama Diallo; Bruno Canard; Chantal Rabourdin-Combe; Hélène Valentin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Viral immunosuppression: disabling the guards.

Authors:  Marco Colonna
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

3.  Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease.

Authors:  Jolanda D F de Groot-Mijnes; Jessica M van Dun; Robbert G van der Most; Raoul J de Groot
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Sphingosine analog AAL-R promotes activation of LCMV-infected dendritic cells.

Authors:  Young-Jin Seo; Bumsuk Hahm
Journal:  Viral Immunol       Date:  2014-03       Impact factor: 2.257

Review 5.  Measles virus-induced immunosuppression: from effectors to mechanisms.

Authors:  Elita Avota; Evelyn Gassert; Sibylle Schneider-Schaulies
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

6.  Measles virus targets DC-SIGN to enhance dendritic cell infection.

Authors:  Lot de Witte; Marion Abt; Sibylle Schneider-Schaulies; Yvette van Kooyk; Teunis B H Geijtenbeek
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Receptor-dependent coronavirus infection of dendritic cells.

Authors:  Brian C Turner; Erin M Hemmila; Nicole Beauchemin; Kathryn V Holmes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Canine distemper virus selectively inhibits apoptosis progression in infected immune cells.

Authors:  Stéphane Pillet; Veronika von Messling
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

9.  Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression.

Authors:  Bumsuk Hahm; Nathalie Arbour; Michael B A Oldstone
Journal:  Virology       Date:  2004-06-01       Impact factor: 3.616

10.  Cell-cell fusion induced by measles virus amplifies the type I interferon response.

Authors:  F Herschke; S Plumet; T Duhen; O Azocar; J Druelle; D Laine; T F Wild; C Rabourdin-Combe; D Gerlier; H Valentin
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.